Select publications

Czuczman MS et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22(23):Epub ahead of print. Abstract

Grillo-Lopez AJ. Rituximab (Rituxan/MabThera): The first decade (1993-2003). Expert Rev Anticancer Ther 2003;3(6):767-79. Abstract

Hagenbeek A et al. Rituximab therapy for indolent non-Hodgkin’s lymphoma. Anticancer Drugs 2002;13(Suppl 2):11-7. Abstract

Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004;31(1 Suppl 2):17-21. Abstract

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl);Abstract 6502.

Jazirehi AR et al. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 2004;64(19):7117-26. Abstract

Kimby E. Beyond immunochemotherapy: Combinations of rituximab with cytokines interferonalpha2a and granulocyte-macrophage colony stimulating factor. Semin Oncol 2002;29(2 Suppl 6):7- 10. Abstract

Lyman GH et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non- Hodgkin’s lymphoma: A nationwide study. J Clin Oncol 2004;22(21):4302-11. Abstract

Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma. Proc ASH 2003;Abstract 87.

McLaughlin P et al. Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab® monoclonal antibody therapy, with interferon maintenance. Proc ASCO 2003;Abstract 2269.

Morel P et al. Autologous stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and overexpression of bcl2 protein. Results of the first interim analysis of the GELA trial LNH98-B2. J Clin Oncol 2004;22(14 Suppl);Abstract 6505.

Nademanee A et al. High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin’s lymphoma (NHL): Update of a phase I/II trial. J Clin Oncol 2004;22(14 Suppl);Abstract 6504.

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3- weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104(3):634-41. Abstract

Pfreundschuh MG et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis. J Clin Oncol 2004;22(14 Suppl);Abstract 6500.

Rothe A et al. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89(7):875-6. Abstract

Shimoni A et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin’s lymphoma. Br J Haematol 2003;122(3):457-64. Abstract

Shipley DL et al. Phase II trial of rituximab and short duration chemotherapy followed by 90Yibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004;22(14 Suppl);Abstract 6519.

van der Kolk LE et al. Treatment of relapsed B-cell non-Hodgkin’s lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy. Leukemia 2003;17(8):1658-64. Abstract